UNC-0638
CAS.NO: 1255580-76-7 Category: Influenza Virus Mol. Formula: C30H47N5O2 Mol. Wt.: 509.739
| Size | Price | Stock | Quantity |
|---|---|---|---|
| 25 mg | $199 | In stock |
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Description: UNC0638 is an inhibitor of G9a and GLP with excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets. UNC0638 treatment of a variety of cell lines resulted in lower global H3K9me2 levels, equivalent to levels observed for small hairpin RNA knockdown of G9a and GLP with the functional potency of UNC0638 being well separated from its toxicity. UNC0638 markedly reduced the clonogenicity of MCF7 cells, reduced the abundance of H3K9me2 marks at promoters of known G9a-regulated endogenous genes and disproportionately affected several genomic loci encoding microRNAs.
| Synonyms | UNC0638, UNC-0638, UNC 0638 |
| SMILES | CC(C)N1CCC(CC1)NC2=NC(=NC3=CC(=C(C=C32)OC)OCCCN4CCCC4)C5CCCCC5 |
| InChI | InChI=1S/C30H47N5O2/c1-22(2)35-17-12-24(13-18-35)31-30-25-20-27(36-3)28(37-19-9-16-34-14-7-8-15-34)21-26(25)32-29(33-30)23-10-5-4-6-11-23/h20-24H,4-19H2,1-3H3,(H,31,32,33) |
| InChI Key | QOECJCJVIMVJGX-UHFFFAOYSA-N |
| Boiling Point | 563.9±50.0 °C at 760 mmHg |
| Melting Point | 93-94 °C |
| Flash Point | 294.8±30.1 °C |
| Density | 1.1±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : ≥ 30 mg/mL (58.85 mM) |
| Appearance | white solid powder |
| Complexity | 660 |
| Exact Mass | 509.37297576 |
| Index Of Refraction | 1.587 |
| Vapor Pressure | 0.0±1.5 mmHg at 25°C |
| PSA | 62.75000 |
| XLog P3 AA | 6.3 |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Purity | 0.98 |
| In Vitro | UNC0638, an inhibitor of G9a and GLP with excellent potency and selectivity over a wide range of epigenetic and non-epigenetic targets.The Ki of UNC0638 is determined to be 3.0±0.05 nM (n=2). Consistent with this, the Morrison Ki for UNC0638 is 3.7±0.2 nM (n=3). The selectivity of UNC0638 over a wide range of epigenetic targets is evaluated. Notably, UNC0638 is inactive against other H3K9 (SUV39H1 and SUV39H2), H3K27 (EZH2), H3K4 (SETD7, MLL and SMYD3), H3K79 (DOT1L) and H4K20 (SETD8) methyltransferases, as well as PRDM1, PRDM10 and PRDM12. In addition, UNC0638 is inactive against protein arginine methyltransferases PRMT1 and PRMT3, and HTATIP, a histone acetyltransferase. Of note, UNC0638 has weak but measurable activity against JMJD2E (IC50=4,500±1,100 nM), a Jumonji protein demethylase and DNA methyltransferase DNMT1 (IC50=107,000±6,000 nM). Nevertheless, the selectivity of UNC0638 for G9a and GLP over JMJD2E is >200-fold, and selectivity for G9a and GLP over DNMT1 is >5,000-fold. UNC0638 is a type of small molecule that can specifically inhibit the enzyme activity of histone methyltransferase EHMT and reduce the H3K9 dimethylation (H3K9me2) levels in cells. |
| Target | IC50: <15 nM (G9a), 19±1 nM (GLP) |
| Drug Resistance | Drug resistance mechanism: UNC-0638 targets epigenetic modifications by inhibiting the G9a histone methyltransferase, which is implicated in the methylation of histone H3 on lysine 9 (H3K9), a key process in gene silencing and resistance development. Common mutations: Mutations in the EHMT2 gene, encoding G9a, can lead to altered binding sites, reducing UNC-0638's efficacy and causing resistance by maintaining histone methylation levels. Drug resistance-related sites: Specific mutations at the catalytic domain of G9a may prevent UNC-0638 from effectively inhibiting methyltransferase activity, sustaining aberrant gene expression. Cross-resistance: Resistance to UNC-0638 may confer cross-resistance to other G9a inhibitors, as similar binding site alterations can affect multiple compounds targeting the same enzyme. Monitoring suggestions: Regular sequencing of the EHMT2 gene and assessment of histone methylation levels are recommended to detect and manage resistance. |
| Applications | Epigenetic Modulation: UNC-0638 acts as a potent inhibitor of G9a, a histone methyltransferase, offering potential in epigenetic research for antiviral therapies. Gene Expression Studies: By modulating epigenetic marks, UNC-0638 provides insights into the regulation of viral gene expression and replication in host cells. Viral Pathogenesis Research: Utilized in studying the mechanisms of viral pathogenesis, UNC-0638 aids in understanding virus-host interactions at the epigenetic level. Antiviral Drug Development: UNC-0638 serves as a lead compound in the development of novel antiviral agents targeting epigenetic pathways. Infection Control Strategies: Its application in research helps design innovative strategies to control viral infections through epigenetic intervention. |
| Protocol Notes | Storage Conditions: Store UNC-0638 at -20℃. Ensure the product remains stable by keeping it in a tightly sealed container to prevent moisture exposure. Solution Preparation: Dissolve UNC-0638 in DMSO. Prepare a stock solution by dissolving it in DMSO to achieve the desired concentration for experimental use. Operation Precautions: Handle with care. Use personal protective equipment, including gloves and goggles, when handling UNC-0638 to ensure safety during experiments. Stability Monitoring: Monitor UNC-0638 stability. Regularly check the solution for any color changes or precipitation, which may indicate degradation. Light Sensitivity: Protect UNC-0638 from light. Store and handle the compound in a dark environment to maintain its efficacy and stability. |
| Drug Combination | Introduction to UNC-0638 Drug Combination for Scientific Research Enhancing Efficacy: UNC-0638 is often combined with other agents to enhance its efficacy by targeting multiple pathways in cellular processes. Synergistic Strategy: Combining UNC-0638 with histone deacetylase inhibitors can provide synergistic effects, potentially leading to improved gene expression modulation. Resistance Reduction: Using UNC-0638 alongside other epigenetic modulators may reduce the risk of drug resistance by disrupting compensatory mechanisms within the cell. Pharmacokinetic Considerations: Careful examination of pharmacokinetic profiles is essential to avoid altered absorption or metabolism when pairing UNC-0638 with other compounds. Drug Interaction Awareness: Researchers should be aware of potential drug interactions that may arise from combining UNC-0638 with other active substances, affecting overall experimental outcomes. Guided Research Approach: This information serves to guide scientific research, fostering an understanding of UNC-0638's potential when used in combination strategies. |
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Repurposing of Raltitrexed as an Effective G9a/EHMT2 Inhibitor and Promising Anti-Alzheimer’s Agent
Journal: ACS Medicinal Chemistry Letters
Date: 10/12/2023
Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma
Journal: Cancer Letters
Date: 8/1/2023
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer
Journal: Science Translational Medicine
Date: 6/21/2023
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP
Journal: Journal of Medicinal Chemistry
Date: 6/2/2023
G9a/glp inhibitors and methods of use
Patent ID: WO2025024311A2
Still have questions?
![(S)-(+)-Camptothecin-[d5]](https://resource.bocsci.com/structure/1329616-37-6.gif)
![1-Adamantanamine-[d15]](https://resource.bocsci.com/structure/33830-10-3.gif)
